Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=26499177
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Current Management of Primary Immune Thrombocytopenia
#MMPMID26499177
Provan D
; Newland AC
Adv Ther
2015[Oct]; 32
(10
): 875-87
PMID26499177
show ga
Primary immune thrombocytopenia is an autoimmune disorder of unknown cause
affecting both children and adults. The low peripheral blood platelet count is
caused by premature platelet destruction by self-reacting antibodies in addition
to an impairment of platelet production. The disease is heterogeneous in its
pathophysiology, clinical features and responses to treatment. To date, most of
the treatments used have been immune-modulating drugs and these contribute to
increased morbidity and mortality in patients. A new class of drugs, the
thrombopoietin receptor agonists, has been developed for use in ITP. These have
gone through randomised controlled trials in large numbers of patients with ITP.
These drugs have high efficacy and are well tolerated. In addition, around 30% of
patients receiving these drugs are able to stop them and maintain a safe or
normal platelet count. Older treatments such as splenectomy are being used less
than before, largely because of the introduction of the thrombopoietin receptor
agonists. Currently there are trials underway evaluating novel therapies for ITP
that will become available over the next few years once the trials are complete.
free
free
free
